Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.76 SEK | -4.70% | +5.38% | +248.96% |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 397M 36.71M |
---|---|---|---|---|---|
Net income 2024 * | -37M -3.42M | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | 18.35M 1.7M | Net Debt 2025 * | 69M 6.38M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-9.05
x | P/E ratio 2025 * |
-4.8
x | Employees | 13 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 74.72% |
Latest transcript on Ascelia Pharma AB
1 day | -4.70% | ||
1 week | +5.38% | ||
Current month | +11.15% | ||
1 month | +32.13% | ||
3 months | +36.43% | ||
6 months | +295.96% | ||
Current year | +248.96% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 49 | 13-12-31 | |
Director of Finance/CFO | 52 | 19-12-31 | |
Chief Tech/Sci/R&D Officer | 40 | 21-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 69 | 17-05-31 | |
Niels Mengel
BRD | Director/Board Member | 76 | 99-12-31 |
Director/Board Member | 59 | 16-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 11.76 | -4.70% | 1,458,962 |
24-05-02 | 12.34 | +16.64% | 3,636,586 |
24-04-30 | 10.58 | -0.56% | 20,332 |
24-04-29 | 10.64 | -4.66% | 153,180 |
24-04-26 | 11.16 | +5.28% | 118,115 |
Delayed Quote Nasdaq Stockholm, May 03, 2024 at 11:29 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+248.96% | 36.75M | |
+25.69% | 47.9B | |
+46.90% | 41.42B | |
-3.46% | 40.7B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- ACE Stock